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SHORT REPORT
An antisense Bcr-Abl phosphodiester-tailed methylphosphonate 
oligonucleotide reduces the growth of chronic myeloid 
leukaemia patient cells by a non-antisense mechanism
Received 20 September 1996; accepted for publication 21 October 1996
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Summary. The specific of antisense oligonucleotides
targeted to the mRNA breakpoint region of the Bcr-Abl 
oncogene, found in leukaemic cells from patients with 
chronic myeloid leukaemia, remains controversial due to 
non-specific effects. To prevent protein binding of oligo­
nucleotides we designed and tested a methylphosphonate 
oligonucleotide with an attached 3' soluble phosphodiester 
tail. Growth of chronic myeloid leukaemia (CML) cell lines 
BV173, KCL-22 and cells of CML patients tested was 
inhibited by the b2a2 type antisense Bcr-Abl oligonucleotide 
and not with controls. Also the growth of control CD34+
cells of two healthy donors, control cell lines and cells from 
AML patients was only moderately affected or not affected. 
Bcr-Abl protein studies in combination with growth- 
determination experiments indicated that the antisense 
methylphosphonate Bcr-Abl oligonucleotide tested is a 
potent inhibitor of the growth of CML cells but works in a 
non-antisense manner.
Keywords: antisense, oligonucleotides, Bcr-Abl, methylphos­
phonate, apoptosis.
A variety of antisense oligonucleotides targeted to the bcr-abl 
mRNA breakpoint have been used. Modified oligonucleotides 
are more stable in serum, but non-sequence specific effects 
occur (Kirkland et al, 1993; Obrieb et al, 1994; Smetsers et al, 
1995). This is probably caused by binding to proteins as a
charge of the oligonucleotides.
(for
result of the
Antisense phosphorothioates can bind to 
review see Stein, 1995). The uncharged methylphospho- 
nates have been claimed to reduce cell growth by specific 
antisense effects (Tari et al, 1994). The big disadvantage of 
these oligos is their insolubility and they need to be delivered 
to cells in liposomes. In this study we used methylphos­
phonate oligonucleotides targeted to the Bcr-Abl mRNA
junctions. We to overcome liposomal
delivery by adding a charged 3' phosphodiester tail to the 
oligonucleotides to make them soluble in culture medium.
MATERIAL AND METHODS
Antisense oligonucleotides were synthesized and purified by 
the Eurogentec corporation (Eurogentec, Seraing, Belgium).
Correspondence: Dr Ewald J. B. M. Mensink, Department of 
Haematology, University Hospital St Radboud, P.O. Box 9101, 
6500 HB Nijmegen, The Netherlands.
They were dissolved in sterile IMDM and sterilized by 
filtration. The sequence of the oligonucleotides is as follows:
OB2A2.21MET : 5'-CTGAAGGGCTTCTTCCTTATT-3' 
B2A2.21MET ; 5 *-A ATA AGGAAGA AGCCCTTCAG-3' 
d33A2.24MET : 5'-GGGCTTTTGAACTCTGCTTAAATC-3'.
Underlined characters represent methylphosphonate lin­
kages; plain characters represent normal phosphodiester 
linkages.
■ cell lines culture, flow cytometric analysis and 
determination of the Bcr-Abl breakpoint type were carried 
out: as 
tion
. Cryopreserva- 
cells were performed as
described (Willems et al, 1996), SDS PAGE and immurio- 
blotting were performed as described (Meijerink et al, 1995).
RESULTS
Antisense methylphosphonate oligonucleotides of 15 nucleo­
tides and longer are not soluble in aqueous solutions. We 
modified the oligonucleotides described by Tari et al (1994). 
The oligonucleotides used here contain an additional live 
nucleotide long phosphodiester tail at the 3' end of the 
oligonucleotide and could be dissolved in culture medium.
© 1997 Blackwell Science Ltd 377
378 Short Report
The effect of the partial methylphosphonate oligonucleo­
tides on the cell growth of several CML and non-CML cell 
lines was determined at an oligonucleotide concentration of 
.10 pm. Fig 1A shows the cell numbers of these cell lines after
6d in culture. Sense control oligonucleotide B2A2.21MET 
showed no reduction of cell growth of any of the tested 
cell lines. Treatment with antisense oligonucleotide 
aB2A2.21MET resulted in a decrease in cell number of
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Fig 2B. Immunoblot assay of cellular extracts of cell line BV173 and 
KCL-22 after 5 d of treatment with oligonucleotides and K562 after 
2d of treatment with Herbimyein A, AS: aB2A2.21MKT, SE: 
B2A2.21MET; NT: not treated: mut: mutant protein.
CML cell lines BV173 and KCL-22 to 12% and 56% 
respectively, relative to the untreated control. Other cell 
lines were not affected. Oligonucleotide aB3A2.24MET failed
BV173to inhibit the growth of any of the cell lines 
and KCL-22 are both cell lines with a B2A2 type breakpoint. 
The growth of these cell lines is inhibited by an antisense 
oligonucleotide targeted to this breakpoint. Cell line KYOl 
also expresses a bcr-abl mRNA containing this breakpoint, 
but its growth is not affected by the oligonucleotide.
Because the behaviour of CML cell lines in culture can be 
different from primary CML cells (Kirldand et al 1994), we 
also tested cells from CML patients, for which selection was 
based on expression of the bcr-abl mRNA, presence of >5% 
CD34+ cells and in vitro growth of cells. The four CML patient 
cells tested all showed a 20-30% reduced growth, relative to 
the untreated control, when treated with aB2A2.21MET 
(Fig IB). Also one sample (from patient CML4) containing 
CML cells expressing the other B3A2 mRNA was
affected, indicating that the dB2A2.21MET oligonucleotide 
inhibition is not breakpoint specific. Purified CD 34 f cells from 
healthy donors were not inhibited at all by aB2A2.21MET. 
This oligonucleotide only showed a moderate decrease of 
growth to about 70% in three out of the four randomly chosen 
AML patient cells (Fig 1C). Oligonucleotide aB,3A2.24MBT 
showed similar effects although they were less drastic than 
cdB2A2.21MET. Sense control oligonucleotide B2A2.21MET 
did not induce an effect on the growth of any of the tested 
cells.
We used a flow cytometric assay to investigate whether the 
cell growth reduction by the tailed methylphosphonate 
oligonucleotide is caused by an antisense mediated reduction
of the expression of the p210
Bcr-abl
protein (Smetsers et al,
1995). Cell line BV173 expresses only p210Iicr"Ahl and not
p i 45e-nbl, which enables determination of only p210Bcr-Abl
protein expression. Fig 2A shows flow cytometric analysis 
of BV 17 3 cell samples after 5 d of treatment with 
«B2A2.21MET and complementary sense oligonucleotide 
B2A2.21MET in medium containing 10% FCS. Expression of 
Bcr-Abl together with actin, and with DNA was investigated. 
Only in the antisense aB2A2.21MET treated cells could a 
negative cell population with low expression of p210BtT_Abl 
be detected. These cells, however, also had a low expression 
of actin and a population showed a low DNA staining 
(apoptotlc cells). No cells were detected expressing low 
amounts of only actin or only p2108® . This indicates that 
cells simultaneously express lower amounts of actin and 
p210lk:r and some of these cells are apoptotic. A similar, 
but less profound, effect was observed in cell line KCL-22, 
about 1.0% p21.0lk negative cells were present (data not 
shown). Cell lines KYO-1 and K562 showed no Bcr-Abl 
negative cells after treatment (data not shown). Cell line 
KYO-1 also expresses a b2a2 type Bcr-Abl mRNA but 
p2 .10Bcr expression is not reduced.
Protein expression of BV173 and KCL-22 cells after 5 d of 
incubation with oligonucleotides was also analysed using 
immunoblotting (Fig 2B). K562 cells after 2d of treatment 
with Herbimyein A was used as a control for decrease in 
p210Bcr expression. After immunoblotting and screening 
with the anti-abl antibody 8E9 the relative expression of 
p210Bcr'AbI with respect to pl45c"abl was reduced in the 
Herbimyein A treated K562 cells, but not in antisense 
treated KCL-22 cells. In BV173 the relative expression could 
not be determined because this cell line does not express the 
normal p l45c"‘lbl.
Cell line BV173 is the most sensitive cell line to treatment 
with the «B2A2.21MKT methylphosphonate oligonucleo­
tide. It is also the only CML cell line tested that expresses a 
wild-type p.53 (Bl et al, 1992). KCL-22 expresses a truncated 
mutated p53 protein (p53 mut, Fig 213). The p53 protein 
plays a crucial role in the induction of cell death, especially 
when generated by DNA damage (Yonish-Rouach et al, 
1991), No evidence for p53 and bax/bcl-2 mediated cell 
death however could be found, since the expression of 
Bax and p53 protein was not increased in treated cells
(Fig 2).
DISCUSSION
Oligonucleotide aB2A2.21MBT is a growth inhibitor of CML 
cells. An antisense mechanism, however, is not responsible 
for this growth inhibition. Many differences exist between 
the tailed oligonucleotide and liposomal packed full methyl- 
phosphonates (Tari et al, 1994). Full methylphosphonates 
are breakpoint specific and reduce the growth of cell line 
K562. The use of liposomes, however, is likely to target the 
oligonucleotides directly to the cytoplasm. This can increase 
the specificity of the in an a
mediated The use of the
Û-B2A2.21MET has an advantage over 
encapsulated oligonucleotide in that it is more easy to
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prepare and it reduces the growth of both breakpoint types of 
CML cells.
The mechanism of action of this oligonucleotide is not 
known. The oligonucleotide probably hybridizes to another 
RNA or some sequences may induce physiological effects. If 
CML cells are more sensitive to these effects than normal cells 
the oligonucleotide can induce the specific CML growth 
reduction that was observed in this study.
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